small molecule

BAXDELA

DELAFLOXACIN MEGLUMINE

Loss of exclusivityJune 2031latest FDA-listed patent expiry

CompanyMELINTA SUBSIDIARY CORP

Drug detail

Brand name	BAXDELA
Active ingredient	DELAFLOXACIN MEGLUMINE
Strength	EQ 450MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	June 2017
Marketing status	RX

Listed patents

Patent	Expires	Type
7728143	June 2031	substance
RE46617	December 2029	substance
8871938	September 2029	substance
8252813	October 2026	product
8273892	August 2026	substance

Regulatory exclusivity

Code	Expires
GAIN	June 2027
NCE	June 2022

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from MELINTA SUBSIDIARY CORP